Geode Capital Management
ACXP icon

Geode Capital Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Geode Capital Management’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.1K Buy
24,819
+12,402
+100% +$35.2K ﹤0.01% 4155
2025
Q4 		$30.9K Buy
+12,417
New +$59.5K ﹤0.01% 4323
2025
Q3 		– Sell
-7,320
Closed -$74.8K – 4474
2025
Q2 		$74.8K Sell
7,320
-1,254
-15% -$10.1K ﹤0.01% 4135
2025
Q1 		$66.9K Buy
8,574
+1,249
+17% +$16.8K ﹤0.01% 4135
2024
Q4 		$119K Hold
7,325
– – ﹤0.01% 4055
2024
Q3 		$278K Buy
7,325
+824
+13% +$34.9K ﹤0.01% 3795
2024
Q2 		$293K Buy
6,501
+683
+12% +$30K ﹤0.01% 3781
2024
Q1 		$285K Buy
5,818
+211
+4% +$13.7K ﹤0.01% 3813
2023
Q4 		$430K Buy
5,607
+1,177
+27% +$88.8K ﹤0.01% 3669
2023
Q3 		$127K Buy
4,430
+566
+15% +$21.6K ﹤0.01% 4164
2023
Q2 		$205K Hold
3,864
– – ﹤0.01% 4031
2023
Q1 		$267K Hold
3,864
– – ﹤0.01% 3912
2022
Q4 		$307K Buy
3,864
+52
+1% +$3.42K ﹤0.01% 3878
2022
Q3 		$228K Buy
3,812
+3,235
+561% +$242K ﹤0.01% 4126
2022
Q2 		$43K Buy
577
+30
+5% +$2.02K ﹤0.01% 4806
2022
Q1 		$35K Buy
+547
New +$42.9K ﹤0.01% 4872

Other funds holding ACXP

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return

Geode Capital Management's ACXP Position: Q1 2026 in Review

Geode Capital Management increased its Acurx Pharmaceuticals (ACXP) stake by 100% in Q1 2026, buying an estimated $35.2K and bringing the position to 24,819 shares worth $92.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4155.

Geode Capital Management first reported a position in ACXP in Q1 2022 and has held it in 16 quarters since. The position peaked at $430K in Q4 2023. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

  • Geode Capital Management held 24,819 shares of Acurx Pharmaceuticals worth $92.1K as of Q1 2026.
  • Geode Capital Management bought 12,402 Acurx Pharmaceuticals shares in Q1 2026, an estimated $35.2K.
  • Acurx Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4155 holding.
  • Geode Capital Management first reported a position in Acurx Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Geode Capital Management's Acurx Pharmaceuticals position peaked at $430K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.